TG Therapeutics: Promising Investigational Monoclonal Antibody Ublituximab for Relapsing Form of M.S.
August 31, 2022
0
TG Therapeutics Results Published in NEJM TG Therapeutics (TGTX) results from the ULTIMATE I & II Phase 3 trials evaluating the firm’s investigational monoclonal antibody product ublituximab in patients with relapsing forms of multiple sclerosis (RMS) were